- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00957476
Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In addition to the increase in obesity in adult and children, there has been a significant increase in birth weights over the last 2 decades. Based on our preliminary data, maternal pre-gravid obesity is the strongest risk factor for neonatal as well as adolescent obesity. The long-term goals of our research are to examine therapeutic strategies to decrease fetal adiposity. Obesity and pregnancy are both insulin resistant conditions associated with chronic low-grade inflammation. Therefore, we hypothesize that n-3 PUFA dietary supplements during pregnancy will act as insulin sensitizers decreasing peripheral insulin resistance and inflammation. If correct this mechanism should decrease availability of maternal nutrients to the fetus and subsequently reduce adiposity at birth. We plan a prospective randomized double blind control trial of n-3 PUFA supplementation and placebo in overweight/obese women, with a previous cesarean delivery, initiated in early pregnancy and maintained throughout pregnancy. This proposal has two specific aims. Specific aim 1 is to evaluate the effect of n-3 PUFA supplementation on maternal insulin sensitivity. Measures of maternal insulin sensitivity and lipid metabolism will be made using the ISogtt, indirect calorimetry body composition (BODPOD) and plasma lipid profile at baseline and after dietary intervention.
Specific aim 2 will assess the effect of n-3 PUFA on the inflammatory status in overweight/obese pregnant women. We hypothesize that n-3 PUFA supplementation decreases chronic inflammation during pregnancy by preventing monocyte activation and accumulation of macrophages in WAT thus lowering systemic concentration of pro-inflammatory cytokines. We plan to characterize the longitudinal changes in circulating monocytes and plasma adipokines in order to define the inflammatory patterns in both groups over time. We will also determine the abundance and phenotype of macrophages infiltrating WAT using flow cytometry, immunohistochemistry and gene expression profiling. Furthermore, the role of PPARγ as a central target of n-3 PUFA action to regulate insulin sensitivity will be examined by characterizing the expression of PPARγ in WAT of both supplemented and control groups. Additionally, we will investigate the direct affect of n-3 PUFA on the expression of adiponectin and PPARγ regulated genes in primary cultured adipocytes.
In summary, this proposal combines both clinical and molecular methodologies in an overweight/obese subject population in order to assess the effect of n-3 PUFA on inflammation and insulin resistance. Preliminary data will also be obtained on fetal body composition in order to later address the prevention of the long term adverse effects (developmental programming) of maternal obesity in the developing fetus.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- MetroHealth Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI (wt/ht2) > or = 25 at first antenatal visit
- Gestational age at randomization between 8-16 weeks
- No medical problems such as hyperlipidemia, hypertension, or pregestational diabetes
- Between the ages of 18 and 40 years old
- Non-smokers
- No obstetrical problems such as a history of preeclampsia or gestational diabetes
- Confirmed singleton pregnancy
Exclusion Criteria:
- Major fetal anomaly
- Regular intake of fish oil supplements (defined as greater than 500 mg per week within the last four weeks). This is due to the placebo group receiving fish oil outside of the study.
- Daily use of nonsteroidal anti-inflammatory agents
- Allergy to fish or fish products, gluten intolerant (because the placebo contains wheat germ oil, which is not gluten free).
- Women who are vegetarians and do not eat any fish.
- Infants born preterm (less than 36 weeks gestation) or less than 2kg.
- Heparin use or known thrombophilia (thrombophilias include homozygous for Factor V Leiden).
- Moderate or high titer IgG anticardiolipin antibodies or prolonged activated PTT or other indication of presence of lupus anticoagulant, homozygous for prothrombin gene (G20210A) mutation, antithrombin III deficiency.
- Protein S (low levels outside of pregnancy) or Protein C deficiency.
- Hyperhomocysteinemia (due to safety concerns because n-3 may affect bleeding time).
- Hemophiliacs including von Willebrand's disease (because of safety concerns associated with the hemophilia treatment combined with the n-3 supplements).
- Planned termination of pregnancy.
- Current hypertension or current use of antihypertensive medication (including diuretics), due to increased risk of adverse pregnancy outcome.
- Pregestational diabetes due to increased risks of affecting fetal growth. We will not exclude women who develop GDM during pregnancy but consider a sub-analyses of these women depending on the number of subjects. Known maternal medical complications: cancer (including melanoma but excluding other skin cancers).
- Current hyperthyroidism if not adequately controlled.
- Renal disease with altered renal function (serum creatinine > 1.5).
- Epilepsy or other seizure disorder.
- Systemic lupus (not discoid lupus), scleroderma, polymyalgia rheumatic.
- Active liver disease (acute hepatitis, chronic active hepatitis, persistently abnormal liver enzymes).
- Platelet or red blood cell disorder (including idiopathic thrombocytopenia purpura, a history of alloimmune thrombocytopenia in a previous offspring, significant anemia due to hemoglobinopathy but not sickle cell trait. Iron deficiency anemia will NOT be an exclusion as long as the hemoglobin is > 8 gm/dl).
- Chronic pulmonary disease (asthma of any degree of severity is NOT an exclusion).
- Structural, functional or ischemic heart disease. Neither mitral valve prolapse nor paroxysmal supraventricular tachycardia are considered exclusions.
- Known HIV positive with viral load greater than 1,000 copies/ml or CD4 count less than 350/mm3.
- Current or planned cerclage due to interference with the natural cause of delivery.
- Illicit drug or alcohol abuse during current pregnancy.
- At the time of birth, all infants will be evaluated by a pediatrician to make sure that they are healthy. Infants will be excluded from further study if they have any medical problems such as respiratory distress syndrome.
- Infants will also be excluded if they have any problems that exclude them from having estimation of body composition, for e.g. birth weight less than 2 kg.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Omega-3 Fish Oil
800mg DHA & 1200mg EPA
|
800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
|
Placebo Comparator: Placebo
Wheat germ oil
|
800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decreased inflammation during human pregnancy
Time Frame: enrollment (8-16 weeks) to delivery
|
cytokine concentration in plasma, placenta and white adipose tissue
|
enrollment (8-16 weeks) to delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of insulin resistance
Time Frame: enrollment (8-16 weeks) to delivery
|
insulin sensitivity as estimated by OGTT
|
enrollment (8-16 weeks) to delivery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Patrick M Catalano, MD, MetroHealth Medical Center
- Principal Investigator: Sylvie Hauguel-de Mouzon, PhD, MetroHealth Medical Center
Publications and helpful links
General Publications
- Calabuig-Navarro V, Puchowicz M, Glazebrook P, Haghiac M, Minium J, Catalano P, Hauguel deMouzon S, O'Tierney-Ginn P. Effect of omega-3 supplementation on placental lipid metabolism in overweight and obese women. Am J Clin Nutr. 2016 Apr;103(4):1064-72. doi: 10.3945/ajcn.115.124651.
- Berggren EK, Groh-Wargo S, Presley L, Hauguel-de Mouzon S, Catalano PM. Maternal fat, but not lean, mass is increased among overweight/obese women with excess gestational weight gain. Am J Obstet Gynecol. 2016 Jun;214(6):745.e1-5. doi: 10.1016/j.ajog.2015.12.026. Epub 2015 Dec 21.
- Haghiac M, Yang XH, Presley L, Smith S, Dettelback S, Minium J, Belury MA, Catalano PM, Hauguel-de Mouzon S. Dietary Omega-3 Fatty Acid Supplementation Reduces Inflammation in Obese Pregnant Women: A Randomized Double-Blind Controlled Clinical Trial. PLoS One. 2015 Sep 4;10(9):e0137309. doi: 10.1371/journal.pone.0137309. eCollection 2015.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB06-00255
- R01HD057236 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore
Clinical Trials on Omega-3 Fish Oil
-
Nordic Pharma, USANutrasource Pharmaceutical and Nutraceutical Services, Inc.CompletedHealthy VolunteersCanada
-
University of VirginiaNational Center for Complementary and Integrative Health (NCCIH)CompletedFatty Liver | Non-alcoholic SteatohepatitisUnited States
-
October 6 UniversityTanta UniversityUnknown
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)CompletedStress-related Changes in InflammationUnited States
-
Eduardo FerriolliUnknownSarcopenia | Elderly WomenBrazil
-
National Science Council, TaiwanCompletedMajor Depressive EpisodeTaiwan
-
King Fahad Medical CityUnknownBrain Injuries | Ischemic Stroke | Brain Ischemia | Inflammatory Response | Stroke, Acute | Neurologic Dysfunction | Neurological Disorder | Neurological Injury | Permanent Injury
-
AC Camargo Cancer CenterUniversity of Sao PauloCompleted
-
Vachira Phuket HospitalCompleted
-
Federal University of São PauloCompletedNicotine Dependence | Tobacco DependenceBrazil